Publications

All      Ay      Benedict       Cheroutre       Croft       Crotty      Einav       Grifoni       Hogan       Kronenberg      Lisdestam Arlehamn      Myers      Peters      Rao      Reina      Saphire      Schmiedel      Schoenberger      Sette      Sharma      Shresta      Vijayanand      Weiskopf
Altman             Eschweiler      Hedrick       Kawakami      Ley      Pandurangan      Seumois      Von Herrath      
Oct 1, 2011
  • Journal of Virology

Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a high conserved sequence

Stein DA, Perty ST, Buck MD, Oehmen CS, Fischer MA, Poore E, Smith JL, Lancaster AM, Hirsch AJ, Slifka MK, Nelson JA, Shresta S, Fruh K
Jul 1, 2011
  • Expert Review of Anti-infective Therapy

Better late than never: antivirals for dengue

Perry ST, Buck MD, Shresta S
Feb 1, 2011
  • Antiviral Chemistry & Chemotherapy

Important advances in the field of anti-dengue virus research

Julander JG, Perry ST, Shresta S
Feb 1, 2011
  • PLoS Pathogens

STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor

Perry ST, Buck MD, Lada SM, Schindler C, Shresta S
Nov 1, 2010
  • J Immunol

CD4+ T Cells Are Not Required for the Induction of Dengue Virus-Specific CD8+ T Cell or Antibody Responses but Contribute to Protection after Vaccination

Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, Peters B, Sette A, Shresta S
Feb 18, 2010
  • Cell Host Microbe

Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease

Zellweger RM, Prestwood TR, Shresta S
Feb 27, 2025
  • EBioMedicine

A humanised ACE2, TMPRSS2, and FCGRT mouse model reveals the protective efficacy of anti-receptor binding domain antibodies elicited by SARS-CoV-2 hybrid immunity.

Ana-Sosa-Batiz F, Verma SK, Shafee N, Miller R, Conner C, Hastie KM, Timis J, Maule E, Nguyen MN, Tran L, Varghese K, Madany H, Street AE, Zandonatti M, Moi ML, Jarnagin K, Webb DR, Saphire EO, Kim K, Shresta S.
Dec 1, 2024
  • Microbiol Resour Announc

Genomic surveillance of SARS-CoV-2 in Nepal

Khadka B, Napit R, Mihindukulasuriya KA, Shrestha S, Rauniyar R, Tuladhar ET, Droit L, Paredes AM, Jha R, Raut R, Jha BK, Handley SA, Elong-Ngono A, Shresta S, Wang D, Manandhar KD.
Jul 15, 2025
  • Nat Commun

Structural stabilization of the intrinsically disordered SARS-CoV-2 N by binding to RNA sequences engineered from the viral genome fragment

Landeras-Bueno S, Hariharan C, Avalos RD, Norris AS, Snyder DT, Hastie KM, Harkins S, Zandonatti M, Rajamanickam RR, Olmedillas E, Miller R, Shresta S, Wysocki VH, Saphire EO
Apr 3, 2025
  • JCI Insight

Enhanced durability of a Zika virus self-amplifying RNA vaccine through combinatorial OX40 and 4-1BB agonism

Lu HH, Dos Santos Alves RP, Li QH, Eder L, Timis J, Madany H, Chuensirikulchai K, Varghese KV, Singh A, Le Tran L, Street A, Elong Ngono A, Croft M, Shresta S
Jul 22, 2025
  • Cell Rep

Structure of a SARS-CoV-2 spike S2 subunit in a pre-fusion, open conformation

Olmedillas E, Rajamanickam RR, Avalos RD, Ana-Sosa-Batiz F, Zyla D, Zandonatti MA, Harkins SS, Shresta S, Hastie KM, Saphire EO
Dec 1, 2025
  • NPJ Vaccines

Co-immunization with spike and nucleocapsid based DNA vaccines for long-term protective immunity against SARS-CoV-2 Omicron

Pinto PBA, Timis J, Chuensirikulchai K, Li QH, Lu HH, Maule E, Nguyen M, Alves RPDS, Verma SK, Ana-Sosa-Batiz F, Valentine K, Landeras-Bueno S, Kim K, Hastie K, Saphire EO, Alves A, Elong Ngono A, Shresta S.